UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 17, 2010 (November 16,
2010)
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-51312
|
|
54-2155579
|
(State
or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
262400
The
People’s Republic of China
(Address
of principal executive offices, including zip code)
(86)
536-6295802
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02
|
Results
of Operations and Financial
Conditions
|
On
November 16, 2010, Shengtai Pharmaceutical, Inc. (the “Company”) issued a press
release announcing its results for the year ended September 30, 2010. The
Company will host a management conference call to discuss the results at 7:00
a.m. (Pacific)/10:00 a.m. (Eastern)/11:00 p.m. (Shandong/Hong Kong) on
Wednesday, November 17, 2010. The press release is attached as Exhibit 99.1 to
this report on Form 8-K.
The
information in this Current Report, including Exhibit 99.1, shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or incorporated subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by
reference in any registration statement or other document filed under the
Securities Act or the Exchange Act, whether made before or after the date
hereof, regardless of any general incorporation language in such filings, except
as shall be expressly set forth by specific reference in such a
filing.
Item
9.01
|
Financial
Statements and Exhibits
|
99.1
|
Press
Release of Shengtai Pharmaceutical, Inc., dated November 16,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
|
|
Dated:
November 17, 2010
|
|
|
|
|
By:
|
/s/
Qingtai Liu
|
|
|
Name:
|
Qingtai
Liu
|
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
|
|